22 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28249207	78	Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet?-cells from apoptosis.	East China Normal University
27106709	92	Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.	Korea Research Institute of Chemical Technology
25662701	23	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3ß inhibitors and neuroprotective agents.	Zhejiang University
25178155	40	Discovery of dual death-associated protein related apoptosis inducing protein kinase 1 and 2 inhibitors by a scaffold hopping approach.	Ku Leuven
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077425	197	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	Harvard Medical School
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	Glaxosmithkline
15711537	653	A small molecule-kinase interaction map for clinical kinase inhibitors.	Ambit Biosciences
31693351	473	Discovery of 4	TBA
31097999	18	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.	Cellzome
31647655	114	Kinase Chemodiversity from the Arctic: The Breitfussins.	Uit - The Arctic University of Norway
28135235	71	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.	Novartis Institutes For Biomedical Research